A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients | Poster | Abstract #GG01-24 | Friday, May 15 | 7:00 AM – 7:00 PM ET | Joep de Jong | Room 144C |
Spatial distribution of PSMA PET–positive lesions in biochemical recurrence after radical prostatectomy according to Decipher genomic classifier | Poster | Abstract #IP23-15 | Friday, May 15 | 3:30 PM – 5:30 PM ET | Mohammed Shahait | Room 147A |
Association of biopsy-based genomic classifier and initial treatment for prostate cancer: Results from a national clinical–genomic linkage | Poster | Abstract #IP31-20 | Saturday, May 16 | 9:30 – 11:30 AM ET | Michael S. Leapman | Room 145AB |
Molecular characterization and a showcase clinical study on treatment de-escalation for luminal favorable muscle-invasive bladder cancer | Poster | Abstract #IP35-15 | Saturday, May 16 | 9:30 – 11:30 AM ET | Melissa M. Moran | Room 147A |
A stromal transcriptomic signature is prognostic in high-risk non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin | Poster | Abstract #IP47-05 | Saturday, May 16 | 3:30 – 5:30 PM ET | Joep de Jong | Room 147A |
Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo & BLASST-01 phase 2 clinical trials | Poster | Abstract #IP47-06 | Saturday, May 16 | 3:30 – 5:30 PM ET | Joep de Jong | Room 147A |
Non-luminal subtype is associated with worse overall survival in high-risk non-muscle invasive bladder cancer patients – biomarker results from the Bladder Cancer Prognosis Programme | Poster | Abstract #IP47-07 | Saturday, May 16 | 3:30 – 5:30 PM ET | Joep de Jong | Room 147A |
Examining the impact of TGF-b activity on fibroblast infiltration and immune exclusion in muscle-invasive bladder cancer | Podium | Abstract #PD15-10 | Saturday, May 16 | 4:42 – 4:50 PM ET | Shilpa Gupta | Room 206 |
Transcriptomic characterization of prostate cancer in patients with HIV infection | Poster | Abstract #IP49-18 | Sunday, May 17 | 7:00 – 9:00 AM ET | Michael S. Leapman | Room 145AB |
Genomic classifier results and use of post-prostatectomy treatment among a national cohort of patients with prostate cancer | Poster | Abstract #IP62-22 | Sunday, May 17 | 1:00 – 3:00 PM ET | Michael S. Leapman | Room 146A |
Correlative analysis of the expression of two PET imaging targets, PSMA and ACP3, in large RP cohort from the Decipher GRID registry | Poster | Abstract #IP62-05 | Sunday, May 17 | 1:00 – 3:00 PM ET | Mohammed Shahait | Room 146A |
Prognostic significance of HSP90AB1 expression in prostate cancer: Molecular associations and clinical implications | Poster | Abstract #IP62-16 | Sunday, May 17 | 1:00 – 3:00 PM ET | Alireza Ghoreifi | Room 146A |
Prognostic implications of very high Decipher scores in prostate cancer: Toward a refined genomic risk classification | Poster | Abstract #IP62-06 | Sunday, May 17 | 1:00 – 3:00 PM ET | Rohan Sharma | Room 146A |
Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States | Poster | Abstract #IP80-14 | Monday, May 18 | 9:30 – 11:30 AM ET | Michael S. Leapman | Room 146A |
FAP+FN1+CAV1- cancer associated fibroblasts subtype is associated with aggressive behavior of localized prostate cancer | Podium | Abstract #PD27-07 | Monday, May 18 | 10:18 – 10:26 AM ET | Mohammed Shahait | Room 206 |